< Home

  • Presentation
  • Biobank / Figures and tables
  • Biocollection Centaure
  • Newsletter


The DIVAT Biocollection (Ethical Research Committee Agreement) is composed of plasma, serum, blood cells and urines (cool/recent/not frozen and RNA), of all kidney or kidney/pancreas recipients before transplant and at 6 months, 1 year, 3 years and 5 years post-transplant. The samples will also be collected when intercurrent events appear during the transplant follow-up.
Depending on protocols, samples from patients with kidney failure/insufficiency, from healthy patients or donors are collected as well. All patients’ samples of the DIVAT-Biocollection are part of the project aiming at developing, leading and coordinating treatment, cognitive or diagnosis protocols in kidney or pancreas transplant including several main goals:

  1. to identify and validate new molecule markers to predict tolerance, chronic rejection and other graft pathologies
  2. to transfer these markers from “bench to clinic” applications
  3. to manage therapeutic or cognitive clinical trials in order to improve graft outcome

The DIVAT Biocollection has been cited as an example during the last clinic seminar of Biocollection presentation, organized by the IFR 26 on January 10, 2012 in Nantes. To read this presentation, click here.



Newsletter Biocollection #1

Pour consulter la newsletter, suivre le lien.

Biobank / Figures and tables


Biobank Centaure


Biobank presentation



The DIVAT Biocollection (Ethical Research Committee Agreement) is composed of plasma, serum, blood cells and urines (cool/recent/not frozen and RNA), of all kidney or kidney/pancreas recipients before transplant and at 6 months, 1 year, 3 years and 5 years post-transplant. The samples will also be collected when intercurrent events appear during the transplant follow-up.
Depending on protocols, samples from patients with kidney failure/insufficiency, from healthy patients or donors are collected as well. All patients’ samples of the DIVAT-Biocollection are part of the project aiming at developing, leading and coordinating treatment, cognitive or diagnosis protocols in kidney or pancreas transplant including several main goals:

  1. to identify and validate new molecule markers to predict tolerance, chronic rejection and other graft pathologies
  2. to transfer these markers from “bench to clinic” applications
  3. to manage therapeutic or cognitive clinical trials in order to improve graft outcome

The DIVAT Biocollection has been cited as an example during the last clinic seminar of Biocollection presentation, organized by the IFR 26 on January 10, 2012 in Nantes. To read this presentation, click here.